RGNT Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.880

Open

2.713

VWAP

2.82

Vol

17.66K

Mkt Cap

14.86M

Low

2.699

Amount

49.74K

EV/EBITDA(TTM)

--

Total Shares

5.18M

EV

8.68M

EV/OCF(TTM)

--

P/S(TTM)

--

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

Show More

Events Timeline

(ET)

2026-04-16

08:40:00

Regentis Biomaterials Collaborates with Humanitas Research Hospital

2026-03-17 (ET)

2026-03-17

09:10:00

Regentis Biomaterials Launches Solvent-Free GelrinC Manufacturing Process

2026-02-19 (ET)

2026-02-19

08:50:00

Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer

2026-02-17 (ET)

2026-02-17

08:50:00

Regentis Biomaterials Expands European Clinical Network

2026-02-04 (ET)

2026-02-04

09:00:00

Regentis Biomaterials Appoints Ori Gon as CFO and CBO

2026-01-29 (ET)

2026-01-29

08:50:00

Regentis Biomaterials Expands U.S. Clinical Site Network

2026-01-28 (ET)

2026-01-28

11:10:00

Regentis Biomaterials Ltd Trading Halted Due to Volatility

2026-01-20 (ET)

2026-01-20

09:00:00

Regentis Biomaterials Releases New GelrinC Clinical Trial Data

News

seekingalpha

02-24seekingalpha

Regentis Biomaterials Financial Overview and IPO Pricing

seekingalpha

02-04seekingalpha

Regentis Biomaterials Appoints New CFO Ahead of IPO

Newsfilter

02-04Newsfilter

Regentis Appoints New CFO to Drive GelrinC Commercialization

stocktwits

01-16stocktwits

Regentis Biomaterials Stock Surges Nearly 15% Amid 2,990% Follower Increase on Stocktwits

Globenewswire

2025-12-05Globenewswire

Regentis Biomaterials Closes IPO Raising $10 Million

Globenewswire

2025-12-04Globenewswire

Regentis Biomaterials Prices IPO at $8.00 per Share, Raising $10 Million

Valuation Metrics

The current forward P/E ratio for Regentis Biomaterials Ltd (RGNT.A) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Regentis Biomaterials Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding RGNT

Trading Trends

People Also Watch

Frequently Asked Questions

What is Regentis Biomaterials Ltd (RGNT) stock price today?

The current price of RGNT is 2.87 USD — it has decreased -1.37

What is Regentis Biomaterials Ltd (RGNT)'s business?

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

What is the price predicton of RGNT Stock?

Wall Street analysts forecast RGNT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGNT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regentis Biomaterials Ltd (RGNT)'s revenue for the last quarter?

Regentis Biomaterials Ltd revenue for the last quarter amounts to NaN USD, decreased

What is Regentis Biomaterials Ltd (RGNT)'s earnings per share (EPS) for the last quarter?

Regentis Biomaterials Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Regentis Biomaterials Ltd (RGNT). have?

Regentis Biomaterials Ltd (RGNT) has 0 emplpoyees as of May 04 2026.

What is Regentis Biomaterials Ltd (RGNT) market cap?

Today RGNT has the market capitalization of 14.86M USD.